Skip to content

Oncology

Study findings updated . AI-assisted evidence summary, not individual medical advice or a clinician endorsement.

Key findings

74% higher odds of deathUS adults with COVID on recent cancer treatment vs those without cancer (odds ratio)

Recent cancer treatment, not past cancer, was linked to higher COVID deaths.

Among over half a million US adults with COVID-19, 7.8% of those who had radiation or drug therapy for cancer in the prior 3 months died, vs 5.0% of cancer patients without recent treatment and 1.6% of people without cancer. After adjustment, recent treatment meant 74% higher odds of death; patients without recent treatment fared similar to or better than people without cancer.

The danger tracked active treatment more than a cancer label, so people in treatment needed the most protection, while many survivors who had finished therapy faced risks closer to everyone else's. This health-record study from 2020, before vaccines, shows links rather than causes; patients getting treatment may have been sicker in ways the data missed.

See the evidence

A US cohort study of electronic health records for adults diagnosed with COVID-19 between January and December 2020, comparing people with and without cancer.

From the study: “mortality rate: 1.6% for patients without cancer, 5.0% for patients with no recent cancer treatment, and 7.8% for patients with recent cancer treatment”

74% higher odds of death

Chavez-MacGregor M et al. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA oncology. 2022.

From the study: “a higher risk of death (OR, 1.74; 95% CI, 1.54-1.96)”

74% higher odds of death

Chavez-MacGregor M et al. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA oncology. 2022.

From the study: “patients with recent cancer treatment (within 3 months before COVID-19 diagnosis) consisting of radiation therapy or systemic therapy”

74% higher odds of death

Chavez-MacGregor M et al. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA oncology. 2022.

1 in 3 adults diedAdults with blood cancers and COVID-19 in early-pandemic studies, mostly hospitalized

About a third of adults with blood cancers and COVID-19 died.

Across early-pandemic studies, 34% of adults with blood cancers who got COVID-19 died; most were hospitalized. The death rate was 47% for those 60 and older versus 25% for those under 60. Children with blood cancers fared far better, with a 4% death rate.

It marked adults with blood cancers, especially older ones, as among the people most endangered by COVID-19, while children with the same cancers were relatively spared. Pooled mostly from hospitalized patients early in 2020, it likely overstates risk for milder cases, and death rates for cancer patients fell markedly later in the pandemic.

See the evidence

A meta-analysis of 34 adult and 5 pediatric studies covering 3377 patients with blood cancers in Asia, Europe and North America, searched through August 2020.

From the study: “Risk of death among adult patients was 34% (95% CI, 28-39; N = 3240) in this sample of predominantly hospitalized patients.”

1 in 3 adults died

Vijenthira A et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020.

From the study: “patients aged 60 years and older had a significantly higher risk of death than patients under 60 years (47% vs 25%; RR, 1.82; 95% CI, 1.45-2.27; P < .00001)”

1 in 3 adults died

Vijenthira A et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020.

From the study: “The risk of death in pediatric patients was 4% (95% CI, 1-9; N = 102).”

1 in 3 adults died

Vijenthira A et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020.

Down to 1 in 614-day COVID death rate in cancer patients in the second wave, down from 1 in 4

COVID death rates in cancer patients fell between Europe's first two waves.

In a European registry of people with cancer and COVID-19, 25.6% of those diagnosed in the first outbreak (February to June 2020) died within 14 days, vs 16.2% in the second (July 2020 to February 2021). After adjusting for age, tumor stage, other illnesses and treatments, first-outbreak patients still had an 85% higher risk of death at 14 days (hazard ratio).

The terrifying death rates of spring 2020 were not fixed; the authors link the improvement to earlier diagnosis, better hospital care and changing community spread. Patients were reported by cancer centers, so milder cases may be missed, and the registry cannot say exactly why deaths fell.

See the evidence

OnCovid registry data on 2634 patients with cancer and COVID-19 at 35 institutions in 6 European countries, diagnosed February 2020 to February 2021.

From the study: “The 14-day CFRs for the first and second major outbreaks were 25.6% (95% CI, 0.23-0.28) vs 16.2% (95% CI, 0.13-0.19; P < .001), respectively.”

Down to 1 in 6

OnCovid Study Group et al. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. JAMA oncology. 2022.

From the study: “patients diagnosed in the first outbreak had an increased risk of death at 14 days (hazard ratio [HR], 1.85; 95% CI, 1.47-2.32)”

Down to 1 in 6

OnCovid Study Group et al. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. JAMA oncology. 2022.

From the study: “across 2 major outbreaks (February to June 2020 and July 2020 to February 2021)”

Down to 1 in 6

OnCovid Study Group et al. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. JAMA oncology. 2022.

47.0% protectionTwo-dose protection against infection at 3–6 months in cancer patients; 61.4% in others

Vaccine protection faded faster in people with cancer than in others.

In England, two vaccine doses gave people with cancer 65.5% protection against infection, close to the 69.8% in a general-population comparison group. But 3 to 6 months after the second dose, protection had fallen to 47.0% in the cancer group vs 61.4% in the comparison group. Protection was lowest in blood cancers, driven by lymphoma and leukemia.

Vaccines clearly helped people with cancer, but their protection faded faster than in others, so the timing of later doses and extra precautions mattered more for them. A test-negative study from before Omicron that counted infections, not severe illness, so later variants and boosters may change the picture.

See the evidence

A national test-negative case-control study linking PCR tests and vaccine records for adults with cancer and a general-population comparison group in England, December 2020 to October 2021.

From the study: “Overall vaccine effectiveness was 69·8% (95% CI 69·8-69·9) in the control population and 65·5% (65·1-65·9) in the cancer cohort.”

47.0% protection

Lee LYW et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. The Lancet. Oncology. 2022.

From the study: “Vaccine effectiveness at 3-6 months was lower in the cancer cohort (47·0%, 46·3-47·6) than in the control population (61·4%, 61·4-61·5).”

47.0% protection

Lee LYW et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. The Lancet. Oncology. 2022.

From the study: “was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia”

47.0% protection

Lee LYW et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. The Lancet. Oncology. 2022.

39.5% made antibodiesPeople with CLL, a blood cancer, after two Pfizer doses

Many people with CLL made no antibodies after COVID vaccination.

Among 167 Israeli patients with chronic lymphocytic leukemia (CLL), a slow-growing blood cancer, only 39.5% made antibodies after two Pfizer doses. Response was 79.2% in people in remission after treatment, 55.2% in never-treated patients and 16.0% in those on treatment. None who had anti-CD20 antibody drugs, which deplete antibody-making B cells, in the prior 12 months responded.

For people with blood cancers a shot did not guarantee protection, and recent anti-CD20 drugs were the biggest red flag for a missing antibody response. A small single-country study that measured antibodies only, not infections or other immune defenses such as T cells.

See the evidence

A study in Israel of 167 adults with CLL and 52 matched healthy volunteers, vaccinated with Pfizer between December 2020 and February 2021.

From the study: “In a total of 167 patients with CLL, the antibody response rate was 39.5%.”

39.5% made antibodies

Herishanu Y et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021.

From the study: “highest in patients who obtained clinical remission after treatment (79.2%), followed by 55.2% in treatment-naive patients and 16.0% in patients under treatment at the time of vaccination.”

39.5% made antibodies

Herishanu Y et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021.

From the study: “None of the patients exposed to anti-CD20 antibodies <12 months before vaccination responded.”

39.5% made antibodies

Herishanu Y et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021.

3.9 million missedUS breast cancer screenings lost in 2020, plus 3.8 million colorectal

Breast cancer screening nearly stopped in April 2020, then mostly rebounded.

In US insurance claims, screening in April 2020 fell 90.8% for breast cancer, 79.3% for colorectal and 63.4% for prostate compared with 2019; breast and prostate screening nearly recovered by July. Projected across the US population, the gap meant about 3.9 million missed breast, 3.8 million colorectal and 1.6 million prostate screenings.

Screening catches cancers early, when they are easiest to treat, so millions of skipped tests raised fears that cancers would surface later and at more advanced stages. Based on one large insurer's claims, so uninsured people are missing and the national deficit is an extrapolation.

See the evidence

A retrospective analysis of insurance claims covering about 60 million people in commercial and Medicare Advantage plans, comparing January to July of 2018, 2019 and 2020.

From the study: “Screening for all 3 cancers declined sharply in March through May of 2020 compared with 2019, with the sharpest decline in April (breast, -90.8%; colorectal, -79.3%; prostate, -63.4%)”

3.9 million missed

Chen RC et al. Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic. JAMA oncology. 2021.

From the study: “The absolute deficit across the US population in screening associated with the COVID-19 pandemic was estimated to be 3.9 million (breast), 3.8 million (colorectal), and 1.6 million (prostate).”

3.9 million missed

Chen RC et al. Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic. JAMA oncology. 2021.

Rebounded by 2021New US cancer diagnoses dipped in 2020, then returned to prepandemic levels

US cancer diagnoses dipped in 2020 but recovered in 2021.

The official US cancer statistics report found new cancer diagnoses fell in 2020 across all demographic groups, then returned to prepandemic levels in 2021. The share of cancers found at a late stage rose in 2020 but fell back in 2021, except for cervical and prostate cancer. Overall cancer death rates kept declining, even during the pandemic.

Diagnoses bounced back fast and cancer death rates kept falling, suggesting the 2020 disruption did not reverse long-term progress against cancer, at least so far. Diagnosis data run only through 2021, and the authors caution that cancers missed in 2020 may still appear later at advanced stages.

See the evidence

The 2025 Annual Report to the Nation by the American Cancer Society, CDC, National Cancer Institute and cancer registries, with diagnoses through 2021 and deaths through 2022.

From the study: “Disruptions in health care use early in the pandemic resulted in incidence declines in 2020, but 2021 incidence returned to prepandemic levels.”

Rebounded by 2021

Sherman RL et al. Annual Report to the Nation on the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic. Cancer. 2025.

From the study: “cancers increased in 2020 for all sites combined and for most screenable cancers, this pattern reversed in 2021 except for cervix and prostate cancers.”

Rebounded by 2021

Sherman RL et al. Annual Report to the Nation on the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic. Cancer. 2025.

From the study: “Overall cancer mortality declined over 20 years, even during the COVID-19 pandemic.”

Rebounded by 2021

Sherman RL et al. Annual Report to the Nation on the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic. Cancer. 2025.

49% lower death riskLung cancer patients given a COVID mRNA shot near immunotherapy start (hazard ratio)

A COVID mRNA shot was linked to longer survival on immunotherapy.

People with advanced lung cancer who got a COVID mRNA vaccine within 100 days of starting checkpoint-inhibitor immunotherapy (drugs that release the immune system's brakes) lived a median 37.3 months vs 20.6 months for unvaccinated patients; 3-year survival was 55.7% vs 30.8%. After adjustment, their risk of death was 49% lower.

Flu and pneumonia shots showed no such link, and mouse experiments suggest the mRNA shot sets off an immune alarm (interferon) that primes T cells against tumors; a randomized trial is needed to confirm it. A retrospective single-center study, so vaccinated patients may have differed in unmeasured ways; only a randomized trial can show the vaccine causes better survival.

See the evidence

A retrospective study at MD Anderson Cancer Center of 180 vaccinated and 704 unvaccinated patients with stage III/IV lung cancer on immunotherapy, 2015 to 2022, plus a melanoma cohort and mouse experiments.

From the study: “we found that receipt of a COVID-19 mRNA vaccine within 100 days of initiation of ICI was associated with significantly improved median OS (20.6 months versus 37.3 months)”

49% lower death risk

Grippin AJ et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025.

From the study: “3 year OS (30.8% versus 55.7%, adjusted hazard ratio (HR adj = 0.51, 95% confidence interval (CI) = 0.37–0.71, P < 0.0001)”

49% lower death risk

Grippin AJ et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025.

Study-specific findings. Different populations, treatments and follow-up periods can produce different results.

Browse all 0 recorded findingsSearch the original results, comparisons and study details.
0 of 0 source groupsFindings stay together with their study.

The research starts here.

No study findings are available in this monitor yet.

Browse the 10 original sourcesThe complete bibliography behind this monitor.
  1. [1]

    Kim, Hyun-Kyung et al.. Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in patients with cancer: Evidence from a nationwide target trial emulation.. The Journal of infection. 2026.

    Open original source in a new tab
  2. [2]

    Parker, Edward P K et al.. Factors associated with severe COVID-19 in immunocompromised subgroups in England from 2020 to 2024: an OpenSAFELY cohort study.. EBioMedicine. 2026.

    Open original source in a new tab
  3. [3]

    Chavez-MacGregor M et al. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA oncology. 2022.

    Open original source in a new tab
  4. [4]

    Vijenthira A et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020.

    Open original source in a new tab
  5. [5]

    OnCovid Study Group et al. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. JAMA oncology. 2022.

    Open original source in a new tab
  6. [6]

    Lee LYW et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. The Lancet. Oncology. 2022.

    Open original source in a new tab
  7. [7]

    Herishanu Y et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021.

    Open original source in a new tab
  8. [8]

    Chen RC et al. Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic. JAMA oncology. 2021.

    Open original source in a new tab
  9. [9]

    Sherman RL et al. Annual Report to the Nation on the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic. Cancer. 2025.

    Open original source in a new tab
  10. [10]

    Grippin AJ et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025.

    Open original source in a new tab

About this collection.

Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results. Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed.

Download and methodology

Download the findings and bibliography displayed in this page snapshot. Values and confidence intervals remain as reported text; this is not a pooled estimate or a systematic review. Product-label observations and editorial takeaways are excluded.

These findings may omit evidence or contain errors and have not been reviewed by a clinician. A citation or download does not establish source verification. Read the original studies for their methods and limitations.

The October 2026 COVID citation audit found errors in this collection. These downloads may still contain affected findings and bibliography entries. Read the correction record before using them.

“Added” dates record entry into the monitor, not publication or clinical review. A null original acquisition or derivation means its historical record is unknown; a current record or verification has its own observation time. The SHA-256 snapshot identifier binds the downloadable public fields. CSV includes finding rows and bibliography-only source rows; JSON includes both lists. Spreadsheet-sensitive CSV cells begin with an apostrophe for safety; JSON preserves the original text.

For attribution, cite ModernDoc and the page URL, data update date and snapshot identifier in the download. Original studies retain their own rights; this download does not grant a licence to their full text.